Phase II trial assessing the efficacy and tolerability of L 759274 in patients with generalised anxiety disorder.

Trial Profile

Phase II trial assessing the efficacy and tolerability of L 759274 in patients with generalised anxiety disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2012

At a glance

  • Drugs L 759274 (Primary)
  • Indications Generalised anxiety disorder
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 28 May 2012 New trial record
    • 20 Mar 2012 Results published in International Journal of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top